1. Knepper MA, Kwon TH, Nielsen S. Molecular physiology of water balance.
N Engl J Med 2015;372:1349–1358.
2. Choi HJ, Yoon YJ, Kwon YK, et al. Patterns of gene and metabolite define the effects of extracellular osmolality on kidney collecting duct.
J Proteome Res 2012;11:3816–3828.
3. Hwang GS, Yang JY, Ryu DH, Kwon TH. Metabolic profiling of kidney and urine in rats with lithium-induced nephrogenic diabetes insipidus by (1)H-NMR-based metabonomics.
Am J Physiol Renal Physiol 2010;298:F461–F470.
4. Schnermann J, Chou CL, Ma T, Traynor T, Knepper MA, Verkman AS. Defective proximal tubular fluid reabsorption in transgenic aquaporin-1 null mice.
Proc Natl Acad Sci U S A 1998;95:9660–9664.
5. Nielsen S, Smith BL, Christensen EI, Knepper MA, Agre P. CHIP28 water channels are localized in constitutively water-permeable segments of the nephron.
J Cell Biol 1993;120:371–383.
6. Vallon V, Verkman AS, Schnermann J. Luminal hypotonicity in proximal tubules of aquaporin-1-knockout mice.
Am J Physiol Renal Physiol 2000;278:F1030–F1033.
7. Pallone TL, Turner MR, Edwards A, Jamison RL. Counter-current exchange in the renal medulla.
Am J Physiol Regul Integr Comp Physiol 2003;284:R1153–R1175.
8. Jung HJ, Kwon TH. Molecular mechanisms regulating aquaporin-2 in kidney collecting duct.
Am J Physiol Renal Physiol 2016;311:F1318–F1328.
9. Kwon TH, Frøkiær J, Nielsen S. Regulation of aquaporin-2 in the kidney: a molecular mechanism of body-water homeostasis.
Kidney Res Clin Pract 2013;32:96–102.
10. Nielsen S, Frøkiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine.
Physiol Rev 2002;82:205–244.
11. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.
Endocr Rev 2013;34:278–301.
12. Rossier BC, Bochud M, Devuyst O. The hypertension pandemic: an evolutionary perspective.
Physiology (Bethesda) 2017;32:112–125.
13. Kwon TH, Laursen UH, Marples D, et al. Altered expression of renal AQPs and Na(+) transporters in rats with lithium-induced NDI.
Am J Physiol Renal Physiol 2000;279:F552–F564.
14. Kortenoeven ML, Fenton RA. Renal aquaporins and water balance disorders.
Biochim Biophys Acta 2014;1840:1533–1549.
15. Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system.
Physiol Rev 2001;81:1197–1267.
16. Verney EB. The antidiuretic hormone and the factors which determine its release.
Proc R Soc Lond B Biol Sci 1947;135:25–106.
17. Zerbe RL, Robertson GL. Osmoregulation of thirst and vasopressin secretion in human subjects: effect of various solutes.
Am J Physiol 1983;244:E607–E614.
18. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.
Clin Chem 2006;52:112–119.
19. Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure: review and meta-analysis.
Clin Chim Acta 2017;475:36–43.
20. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release.
Am J Physiol 1979;236:F321–F332.
21. Lolait SJ, O’Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus.
Nature 1992;357:336–339.
22. Rosenthal W, Seibold A, Antaramian A, et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus.
Nature 1992;359:233–235.
23. van den Ouweland AM, Dreesen JC, Verdijk M, et al. Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus.
Nat Genet 1992;2:99–102.
24. Pan Y, Metzenberg A, Das S, Jing B, Gitschier J. Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus.
Nat Genet 1992;2:103–106.
25. Arthus MF, Lonergan M, Crumley MJ, et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus.
J Am Soc Nephrol 2000;11:1044–1054.
26. Dorsa DM, Majumdar LA, Petracca FM, Baskin DG, Cornett LE. Characterization and localization of 3H-arginine8-vasopressin binding to rat kidney and brain tissue.
Peptides 1983;4:699–706.
27. Ostrowski NL, Lolait SJ, Bradley DJ, O’Carroll AM, Brownstein MJ, Young WS 3rd. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain.
Endocrinology 1992;131:533–535.
28. Lee JW, Chou CL, Knepper MA. Deep sequencing in microdissected renal tubules identifies nephron segment-specific transcriptomes.
J Am Soc Nephrol 2015;26:2669–2677.
29. Ostrowski NL, Young WS 3rd, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats.
Endocrinology 1993;133:1849–1859.
30. Matsumura Y, Uchida S, Rai T, Sasaki S, Marumo F. Transcriptional regulation of aquaporin-2 water channel gene by cAMP.
J Am Soc Nephrol 1997;8:861–867.
31. Yasui M, Zelenin SM, Celsi G, Aperia A. Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements.
Am J Physiol 1997;272:F443–F450.
32. Rieg T, Tang T, Murray F, et al. Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla.
J Am Soc Nephrol 2010;21:2059–2068.
33. Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E. Regulation of aquaporin-2 trafficking.
Handb Exp Pharmacol 2009;133–157.
34. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization.
J Biol Chem 1999;274:32248–32257.
35. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane.
Proc Natl Acad Sci U S A 1995;92:1013–1017.
36. Ishibashi K, Sasaki S, Fushimi K, et al. Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells.
Proc Natl Acad Sci U S A 1994;91:6269–6273.
37. Rojek A, Füchtbauer EM, Kwon TH, Frøkiaer J, Nielsen S. Severe urinary concentrating defect in renal collecting duct-selective AQP2 conditional-knockout mice.
Proc Natl Acad Sci U S A 2006;103:6037–6042.
38. Yamamoto T, Sasaki S, Fushimi K, et al. Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats.
Am J Physiol 1995;268:C1546–C1551.
39. Katsura T, Gustafson CE, Ausiello DA, Brown D. Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells.
Am J Physiol 1997;272:F817–F822.
40. Fushimi K, Sasaki S, Marumo F. Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel.
J Biol Chem 1997;272:14800–14804.
41. Isobe K, Jung HJ, Yang CR, et al. Systems-level identification of PKA-dependent signaling in epithelial cells.
Proc Natl Acad Sci U S A 2017;114:E8875–E8884.
42. Terris J, Ecelbarger CA, Nielsen S, Knepper MA. Long-term regulation of four renal aquaporins in rats.
Am J Physiol 1996;271:F414–F422.
43. Sandoval PC, Claxton JS, Lee JW, Saeed F, Hoffert JD, Knepper MA. Systems-level analysis reveals selective regulation of Aqp2 gene expression by vasopressin.
Sci Rep 2016;6:34863
44. Hasler U, Mordasini D, Bens M, et al. Long term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells.
J Biol Chem 2002;277:10379–10386.
45. Sandoval PC, Slentz DH, Pisitkun T, Saeed F, Hoffert JD, Knepper MA. Proteome-wide measurement of protein half-lives and translation rates in vasopressin-sensitive collecting duct cells.
J Am Soc Nephrol 2013;24:1793–1805.
46. Hasler U, Nielsen S, Féraille E, Martin PY. Posttranscriptional control of aquaporin-2 abundance by vasopressin in renal collecting duct principal cells.
Am J Physiol Renal Physiol 2006;290:F177–F187.
47. Lee YJ, Lee JE, Choi HJ, et al. E3 ubiquitin-protein ligases in rat kidney collecting duct: response to vasopressin stimulation and withdrawal.
Am J Physiol Renal Physiol 2011;301:F883–F896.
48. Medvar B, Raghuram V, Pisitkun T, Sarkar A, Knepper MA. Comprehensive database of human E3 ubiquitin ligases: application to aquaporin-2 regulation.
Physiol Genomics 2016;48:502–512.
49. Wu Q, Moeller HB, Stevens DA, et al. CHIP regulates aquaporin-2 quality control and body water homeostasis.
J Am Soc Nephrol 2018;29:936–948.
50. Centrone M, Ranieri M, Di Mise A, et al. AQP2 abundance is regulated by the E3-ligase CHIP via HSP70.
Cell Physiol Biochem 2017;44:515–531.
51. Trimpert C, Wesche D, de Groot T, et al. NDFIP allows NEDD4/NEDD4L-induced AQP2 ubiquitination and degradation.
PLoS One 2017;12:e0183774
52. Hasler U, Leroy V, Martin PY, Féraille E. Aquaporin-2 abundance in the renal collecting duct: new insights from cultured cell models.
Am J Physiol Renal Physiol 2009;297:F10–F18.
53. Kim JE, Jung HJ, Lee YJ, Kwon TH. Vasopressin-regulated miRNAs and AQP2-targeting miRNAs in kidney collecting duct cells.
Am J Physiol Renal Physiol 2015;308:F749–F764.
54. Ranieri M, Zahedi K, Tamma G, et al. CaSR signaling down-regulates AQP2 expression via a novel microRNA pathway in pendrin and NaCl cotransporter knockout mice.
FASEB J 2018;32:2148–2159.
55. Bijkerk R, Trimpert C, van Solingen C, et al. MicroRNA-132 controls water homeostasis through regulating MECP2-mediated vasopressin synthesis.
Am J Physiol Renal Physiol 2018;315:F1129–F1138.
56. Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.
Nat Rev Nephrol 2015;11:576–588.
57. Milano S, Carmosino M, Gerbino A, Svelto M, Procino G. Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. An update.
Int J Mol Sci 2017;18:2385
58. Fujiwara TM, Morgan K, Bichet DG. Molecular biology of diabetes insipidus.
Annu Rev Med 1995;46:331–343.
59. Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine.
Science 1994;264:92–95.
60. Sohara E, Rai T, Yang SS, et al. Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation.
Proc Natl Acad Sci U S A 2006;103:14217–14222.
61. Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus.
Semin Nephrol 2008;28:245–251.
62. Babey M, Kopp P, Robertson GL. Familial forms of diabetes insipidus: clinical and molecular characteristics.
Nat Rev Endocrinol 2011;7:701–714.
63. Baylis PH. Osmoregulation and control of vasopressin secretion in healthy humans.
Am J Physiol 1987;253:R671–R678.
64. Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney.
Proc Natl Acad Sci U S A 1993;90:11663–11667.
65. Yasui M, Marples D, Belusa R, et al. Development of urinary concentrating capacity: role of aquaporin-2.
Am J Physiol 1996;271:F461–F468.
66. Ecelbarger CA, Nielsen S, Olson BR, et al. Role of renal aquaporins in escape from vasopressin-induced antidiuresis in rat.
J Clin Invest 1997;99:1852–1863.
67. Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells.
J Biol Chem 1999;274:4934–4938.
68. Stefan E, Wiesner B, Baillie GS, et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells.
J Am Soc Nephrol 2007;18:199–212.
69. Hozawa S, Holtzman EJ, Ausiello DA. cAMP motifs regulating transcription in the aquaporin 2 gene.
Am J Physiol 1996;270:C1695–C1702.
70. Kim HY, Choi HJ, Lim JS, et al. Emerging role of Akt substrate protein AS160 in the regulation of AQP2 translocation.
Am J Physiol Renal Physiol 2011;301:F151–F161.
71. Lee YJ, Song IK, Jang KJ, et al. Increased AQP2 targeting in primary cultured IMCD cells in response to angiotensin II through AT1 receptor.
Am J Physiol Renal Physiol 2007;292:F340–F350.
72. Li C, Wang W, Rivard CJ, Lanaspa MA, Summer S, Schrier RW. Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking.
Am J Physiol Renal Physiol 2011;300:F1255–F1261.
73. Olesen ET, Moeller HB, Assentoft M, MacAulay N, Fenton RA. The vasopressin type 2 receptor and prostaglandin receptors EP2 and EP4 can increase aquaporin-2 plasma membrane targeting through a cAMP-independent pathway.
Am J Physiol Renal Physiol 2016;311:F935–F944.
74. Rao R, Patel S, Hao C, Woodgett J, Harris R. GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.
J Am Soc Nephrol 2010;21:428–437.
75. Pisitkun T, Jacob V, Schleicher SM, Chou CL, Yu MJ, Knepper MA. Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD.
Am J Physiol Renal Physiol 2008;295:F1030–F1043.
76. Procino G, Gerbino A, Milano S, et al. Rosiglitazone promotes AQP2 plasma membrane expression in renal cells via a Ca-dependent/cAMP-independent mechanism.
Cell Physiol Biochem 2015;35:1070–1085.
77. Li S, Qiu M, Kong Y, et al. Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-mediated water homeostasis.
J Am Soc Nephrol 2018;29:2658–2670.
78. Kortenoeven ML, Trimpert C, van den Brand M, Li Y, Wetzels JF, Deen PM. In mpkCCD cells, long-term regulation of aquaporin-2 by vasopressin occurs independent of protein kinase A and CREB but may involve Epac.
Am J Physiol Renal Physiol 2012;302:F1395–F1401.
79. de Rooij J, Zwartkruis FJ, Verheijen MH, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP.
Nature 1998;396:474–477.
80. Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression.
Nat Rev Genet 2011;12:283–293.
81. Jung HJ, Raghuram V, Lee JW, Knepper MA. Genome-wide mapping of DNA accessibility and binding sites for CREB and C/EBPβ in vasopressin-sensitive collecting duct cells.
J Am Soc Nephrol 2018;29:1490–1500.
82. Wang J, Zibetti C, Shang P, et al. ATAC-Seq analysis reveals a widespread decrease of chromatin accessibility in age-related macular degeneration.
Nat Commun 2018;9:1364
83. Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control.
Nat Rev Genet 2012;13:613–626.
84. Hnisz D, Day DS, Young RA. Insulated neighborhoods: structural and functional units of Mammalian gene control.
Cell 2016;167:1188–1200.
85. Shlyueva D, Stampfel G, Stark A. Transcriptional enhancers: from properties to genome-wide predictions.
Nat Rev Genet 2014;15:272–286.
86. Yu MJ, Miller RL, Uawithya P, et al. Systems-level analysis of cell-specific AQP2 gene expression in renal collecting duct.
Proc Natl Acad Sci U S A 2009;106:2441–2446.
87. Schenk LK, Bolger SJ, Luginbuhl K, et al. Quantitative proteomics identifies vasopressin-responsive nuclear proteins in collecting duct cells.
J Am Soc Nephrol 2012;23:1008–1018.
88. Park EJ, Lim JS, Jung HJ, Kim E, Han KH, Kwon TH. The role of 70-kDa heat shock protein in dDAVP-induced AQP2 trafficking in kidney collecting duct cells.
Am J Physiol Renal Physiol 2013;304:F958–F971.
89. Hwang JR, Chou CL, Medvar B, Knepper MA, Jung HJ. Identification of β-catenin-interacting proteins in nuclear fractions of native rat collecting duct cells.
Am J Physiol Renal Physiol 2017;313:F30–F46.
90. Grassmeyer J, Mukherjee M, deRiso J, et al. Elf5 is a principal cell lineage specific transcription factor in the kidney that contributes to Aqp2 and Avpr2 gene expression.
Dev Biol 2017;424:77–89.
91. Yu L, Moriguchi T, Souma T, et al. GATA2 regulates body water homeostasis through maintaining aquaporin 2 expression in renal collecting ducts.
Mol Cell Biol 2014;34:1929–1941.
92. Zhang X, Huang S, Gao M, et al. Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice.
Proc Natl Acad Sci U S A 2014;111:2277–2282.
93. Hasler U, Vinciguerra M, Vandewalle A, Martin PY, Féraille E. Dual effects of hypertonicity on aquaporin-2 expression in cultured renal collecting duct principal cells.
J Am Soc Nephrol 2005;16:1571–1582.
94. Kortenoeven ML, van den Brand M, Wetzels JF, Deen PM. Hypotonicity-induced reduction of aquaporin-2 transcription in mpkCCD cells is independent of the tonicity responsive element, vasopressin, and cAMP.
J Biol Chem 2011;286:13002–13010.
95. Li SZ, McDill BW, Kovach PA, et al. Calcineurin-NFATc signaling pathway regulates AQP2 expression in response to calcium signals and osmotic stress.
Am J Physiol Cell Physiol 2007;292:C1606–C1616.
96. Hasler U, Leroy V, Jeon US, et al. NF-kappaB modulates aquaporin-2 transcription in renal collecting duct principal cells.
J Biol Chem 2008;283:28095–28105.
97. Olesen ET, de Seigneux S, Wang G, et al. Rapid and segmental specific dysregulation of AQP2, S256-pAQP2 and renal sodium transporters in rats with LPS-induced endotoxaemia.
Nephrol Dial Transplant 2009;24:2338–2349.
98. Furey TS. ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions.
Nat Rev Genet 2012;13:840–852.
99. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications.
Cell Res 2011;21:381–395.
100. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?
Genes Dev 2004;18:2046–2059.
101. Weake VM, Workman JL. Histone ubiquitination: triggering gene activity.
Mol Cell 2008;29:653–663.
102. Dancy BM, Cole PA. Protein lysine acetylation by p300/ CBP.
Chem Rev 2015;115:2419–2452.
103. Hyndman KA, Knepper MA. Dynamic regulation of lysine acetylation: the balance between acetyltransferase and deacetylase activities.
Am J Physiol Renal Physiol 2017;313:F842–F846.
104. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R. The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates.
EMBO J 2000;19:1839–1850.
105. Bansal AD, Hoffert JD, Pisitkun T, et al. Phosphoproteomic profiling reveals vasopressin-regulated phosphorylation sites in collecting duct.
J Am Soc Nephrol 2010;21:303–315.
106. Hoffert JD, Pisitkun T, Saeed F, Song JH, Chou CL, Knepper MA. Dynamics of the G protein-coupled vasopressin V2 receptor signaling network revealed by quantitative phosphoproteomics.
Mol Cell Proteomics 2012 11:M111.014613.
107. Jung HJ, Kim SY, Choi HJ, et al. Tankyrase-mediated β-catenin activity regulates vasopressin-induced AQP2 expression in kidney collecting duct mpkCCDc14 cells.
Am J Physiol Renal Physiol 2015;308:F473–F486.
108. Yu Z, Kong Q, Kone BC. Aldosterone reprograms promoter methylation to regulate αENaC transcription in the collecting duct.
Am J Physiol Renal Physiol 2013;305:F1006–F1013.
109. Marumo T, Yagi S, Kawarazaki W, et al. Diabetes induces aberrant DNA methylation in the proximal tubules of the kidney.
J Am Soc Nephrol 2015;26:2388–2397.
110. Zhao Y, Ding C, Xue W, et al. Genome-wide DNA methylation analysis in renal ischemia reperfusion injury.
Gene 2017;610:32–43.
111. Liu Y, Liu P, Yang C, Cowley AW Jr, Liang M. Base-resolution maps of 5-methylcytosine and 5-hydroxymethylcytosine in Dahl S rats: effect of salt and genomic sequence.
Hypertension 2014;63:827–838.
112. Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs.
Pediatr Nephrol 2012;27:2183–2204.
113. Birnbaumer M. Vasopressin receptor mutations and nephrogenic diabetes insipidus.
Arch Med Res 1999;30:465–474.
114. Spanakis E, Milord E, Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance.
J Cell Physiol 2008;217:605–617.
115. Robben JH, Knoers NV, Deen PM. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Am J Physiol Renal Physiol 2005;289:F265–F272.
116. Morello JP, Salahpour A, Laperrière A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
J Clin Invest 2000;105:887–895.
117. Robben JH, Deen PM. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
BioDrugs 2007;21:157–166.
118. Barak LS, Oakley RH, Laporte SA, Caron MG. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus.
Proc Natl Acad Sci U S A 2001;98:93–98.
119. Robben JH, Sze M, Knoers NV, Deen PM. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Am J Physiol Renal Physiol 2007;292:F253–F260.
120. Wüller S, Wiesner B, Löffler A, et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
J Biol Chem 2004;279:47254–47263.
121. Serradeil-Le Gal C, Wagnon J, Garcia C, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
J Clin Invest 1993;92:224–231.
122. Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG, Bouvier M. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
Mol Endocrinol 2004;18:2074–2084.
123. Los EL, Deen PM, Robben JH. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
J Neuroendocrinol 2010;22:393–399.
124. Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Proc Natl Acad Sci U S A 2009;106:12195–12200.
125. Jean-Alphonse F, Perkovska S, Frantz MC, et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.
J Am Soc Nephrol 2009;20:2190–2203.
126. Procino G, Carmosino M, Milano S, et al. β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function.
Kidney Int 2016;90:555–567.
127. Chu JY, Chung SC, Lam AK, Tam S, Chung SK, Chow BK. Phenotypes developed in secretin receptor-null mice indicated a role for secretin in regulating renal water reabsorption.
Mol Cell Biol 2007;27:2499–2511.
128. Charlton CG, Quirion R, Handelmann GE, et al. Secretin receptors in the rat kidney: adenylate cyclase activation and renal effects.
Peptides 1986;7:865–871.
129. Li JH, Chou CL, Li B, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.
J Clin Invest 2009;119:3115–3126.
130. Olesen ET, Rützler MR, Moeller HB, Praetorius HA, Fenton RA. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
Proc Natl Acad Sci U S A 2011;108:12949–12954.
131. Carney S, Morgan T, Ray C, Thompson L. Effect of calcitonin on urine concentration in the rat.
Am J Physiol 1983;244:F432–F435.
132. Bouley R, Lu HA, Nunes P, et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration.
J Am Soc Nephrol 2011;22:59–72.
133. Procino G, Milano S, Carmosino M, et al. Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice.
Kidney Int 2014;86:127–138.
134. Fukuhara S, Sakurai A, Sano H, et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway.
Mol Cell Biol 2005;25:136–146.
135. Wang W, Li C, Kwon TH, Knepper MA, Frøkiaer J, Nielsen S. AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors.
Am J Physiol Renal Physiol 2002;283:F1313–F1325.
136. Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra).
Am J Physiol Renal Physiol 2005;288:F1103–F1112.
137. Sanches TR, Volpini RA, Massola Shimizu MH, et al. Silde-nafil reduces polyuria in rats with lithium-induced NDI.
Am J Physiol Renal Physiol 2012;302:F216–F225.
138. Ando F, Sohara E, Morimoto T, et al. Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway.
Nat Commun 2016;7:13636
139. Cheung PW, Nomura N, Nair AV, et al. EGF receptor inhibition by erlotinib increases aquaporin 2-mediated renal water reabsorption.
J Am Soc Nephrol 2016;27:3105–3116.
140. Tingskov SJ, Hu S, Frøkiær J, Kwon TH, Wang W, Nør-regaard R. Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats.
Am J Physiol Renal Physiol 2018;314:F1020–F1025.
141. Efe O, Klein JD, LaRocque LM, Ren H, Sands JM. Metformin improves urine concentration in rodents with nephrogenic diabetes insipidus.
JCI Insight 2016;1:e88409
142. Li W, Zhang Y, Bouley R, et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase.
Am J Physiol Renal Physiol 2011;301:F309–F318.
143. Procino G, Barbieri C, Carmosino M, et al. Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells.
Pflugers Arch 2011;462:753–766.